Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 16/20 | 0.43 |
| ▸ | PPARG | P37231 | 12/20 | 0.42 |
| ▸ | PPARD | Q03181 | 5/20 | 0.41 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.39 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.39 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.39 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13508518 | 0.96 | PPARA (0.43) | PPARAPPARGPPARDPTPN7DUSP3 | |
| SCHEMBL3690033 | 0.92 | PPARA (0.51) | PPARAPPARGPPARDPTPN7DUSP3 | |
| SCHEMBL3691319 | 0.92 | PPARA (0.42) | PPARAPPARGPPARDPTPN7DUSP3 | |
| SCHEMBL13508516 | 0.91 | PPARA (0.51) | PPARAPPARGPPARDPTPN7DUSP3 | |
| SCHEMBL13508475 | 0.90 | PPARG (0.47) | PPARAPPARGPPARDPTPN7DUSP3 | |
| SCHEMBL3756003 | 0.87 | PPARA (0.41) | PPARAPPARGPPARDPTPN7DUSP3 | |
| SCHEMBL13508550 | 0.85 | PTPN7 (0.45) | PPARAPPARGPPARDPTPN7DUSP3 | |
| SCHEMBL3680701 | 0.83 | PPARA (0.46) | PPARAPPARG | |
| SCHEMBL13508521 | 0.83 | PPARA (0.50) | PPARAPPARGPPARDPTPN7DUSP3 | |
| SCHEMBL3685095 | 0.83 | PPARA (0.49) | PPARAPPARGPPARDPTPN7DUSP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655641-B2 | Sulfonamide derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2010-02-02 | — | — | US | claimed |
| US-20060217433-A1 | Sulfonamide derivatives as ppar modulators | ELI LILLY AND COMPANY (US) | 2006-09-28 | — | — | US | claimed |
| US-7655641-B2 | Sulfonamide derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-7655641-B2 | Sulfonamide derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-7655641-B2 | Sulfonamide derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-20060217433-A1 | Sulfonamide derivatives as ppar modulators | ELI LILLY AND COMPANY (US) | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217433-A1 | Sulfonamide derivatives as ppar modulators | PPARD, PPARA, PPARG | PPARA 2/4885PPARG 3/4885PPARD 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.